Pyxis Oncology, Inc.: updates and filings

PYXSNASDAQHealthcare · Pharmaceutical Preparations

Price

$1.81

November 20, 2026Market cap $216M

What Ploutos Investor adds for Pyxis Oncology

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 2 fiscal years, from 2024
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 79 daysAround Feb 9, 2027 · for Q4 2026

last Nov 5, 2026next Feb 9, 2027

An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 23, 2026 latest annualNov 5, 2026 latest quarterly
  • Nov 19, 2026Regulation FD disclosure, other material events
    Form8-K
  • Nov 16, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 16, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 16, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 13, 2026Amended articles or bylaws, shareholder vote
    Form8-K
  • Nov 5, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 5, 2026Results of operations
    Form8-K
  • Nov 3, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 21, 2026Annual meeting proxy statement
    FormDEF 14A
  • Oct 9, 2026Preliminary proxy statement
    FormPRE 14A
  • Oct 9, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 5, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Oct 2, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 1, 2026Material agreement entered, other material events
    Form8-K
  • Sep 9, 2026Regulation FD disclosure, other material events
    Form8-K
  • Sep 8, 2026Officer or director change, Regulation FD disclosure
    Form8-K
  • Aug 27, 2026Filing
    FormEFFECT
  • Aug 20, 2026Shelf registration for future offerings
    FormS-3
  • Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 13, 2026Results of operations
    Form8-K
  • Jul 10, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jul 2, 2026Material agreement entered, unregistered sale of shares, Regulation FD disclosure
    Form8-K
  • Jul 2, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Jun 15, 2026Shareholder vote
    Form8-K
  • May 14, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 12, 2019.

The full analysis

What do Pyxis Oncology's filings show?

The filings are where every one of Pyxis Oncology's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.